In a recent legal showdown, Natera ( NASDAQ:NTRA ) emerged victorious, navigating a complex patent battle with competitor Ravgen that sent its stock soaring to nearly a two-year high. Despite facing a $57 million setback in damages, significantly less than the initial $410 million sought by Ravgen, Natera remains resilient and is set to achieve cash-flow...
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder;...
